Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Firefly NeuroscienceAIFF 12 Equity-to-Asset is 0.87 as of Jun. 2026, which is 107% above its 10-year median of 0.42. GuruFocus rates AIFF with a GF Score™ of 12/100. The stock has 3 warning signs investors should review. Among 2,887 Software companies, Firefly Neuroscience ranks better than 92.48% on this metric.
Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Firefly Neuroscience's Total Stockholders Equity for the quarter that ended in Jun. 2026 was $14.66 Mil. Firefly Neuroscience's Total Assets for the quarter that ended in Jun. 2026 was $16.77 Mil.
Therefore, Firefly Neuroscience's Equity to Asset Ratio for the quarter that ended in Jun. 2026 was 0.87.
The historical rank and industry rank for Firefly Neuroscience's Equity-to-Asset or its related term are showing as below:
AIFF'
s Equity-to-Asset Range Over the Past 10 Years
Min: -15.64 Med: 0.42 Max: 0.87
Current: 0.87
During the past 5 years, the highest Equity to Asset Ratio of Firefly Neuroscience was 0.87. The lowest was -15.64. And the median was 0.42.
AIFF's Equity-to-Asset is ranked better than 92.48% of 2887
companies
in the Software industry
Industry Median: 0.55
vs AIFF: 0.87
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Firefly Neuroscience Equity-to-Asset Related Terms
Firefly Neuroscience Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for Firefly Neuroscience's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AIFF vs RCT, SMSI, FTFT: Equity-to-Asset Comparison
For the Software - Application subindustry, Firefly Neuroscience's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Firefly Neuroscience Equity-to-Asset vs Software Industry
For the Software industry and Technology sector, Firefly Neuroscience's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Firefly Neuroscience's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Firefly Neuroscience's Equity to Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Firefly Neuroscience (AIFF) has a Equity-to-Asset of 0.87 as of Jun. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Firefly Neuroscience and its competitors. This is 107% above median its historical median of 0.42. According to the industry distribution chart, Firefly Neuroscience ranks #217 out of 2887 companies in the Software industry, placing it in the top 7.5%.
Is Firefly Neuroscience's Equity-to-Asset too high?
Firefly Neuroscience's current Equity-to-Asset of 0.87 is 107% above median its 10-year median of 0.42. The Software industry median Equity-to-Asset is 0.55. Firefly Neuroscience's value of 0.87 is 58.2% above this industry median. Based on the distribution chart, Firefly Neuroscience ranks #217 out of 2887 companies in the Software industry, which is in the top quartile — a strong position relative to peers. Overall, Firefly Neuroscience has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Firefly Neuroscience's Equity-to-Asset compare to RCT and SMSI?
According to the Software industry distribution chart, Firefly Neuroscience ranks #217 out of 2887 companies for Equity-to-Asset. This places Firefly Neuroscience in the top 8% of its industry — outperforming the majority of peers. The industry median Equity-to-Asset is 0.55. Firefly Neuroscience's value of 0.87 is 58.2% above this benchmark. While the company's 10-year median is 0.42 vs. the industry median of 0.55, Firefly Neuroscience has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Software company?
The median Equity-to-Asset among Software companies is 0.55, based on 2,887 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Firefly Neuroscience's current Equity-to-Asset of 0.87 is 58.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Firefly Neuroscience and its competitors. For the Software industry, the median Equity-to-Asset is 0.55 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Firefly Neuroscience's current Equity-to-Asset is 0.87, which is 107% above median its own 10-year median of 0.42. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Firefly Neuroscience stock overvalued right now?
Firefly Neuroscience (AIFF) has a current Equity-to-Asset of 0.87. The current Equity-to-Asset is 0.87, which is 107% above median its 10-year median of 0.42 and 58.2% above the Software industry median of 0.55. Firefly Neuroscience's overall GF Score™ is 12/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Firefly Neuroscience (AIFF), the current Equity-to-Asset is 0.87 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Firefly Neuroscience Inc is an artificial intelligence company advancing precision neuroscience, applying AI and large-scale electrophysiological data to give clinicians a more complete, objective picture of how an individual patient's brain is functioning. The firm is developing neuroscientific solutions that improve outcomes for patients with mental illnesses and cognitive disorders. It is focused on the commercialization of its Brain Network Analytics (BNA) software platform (the "BNA Platform")and the discovery and clinical development of biomarkers that support outcomes for people suffering from mental illnesses and cognitive disorders. The company has one reportable segment: the BNA platform. The Company derives revenue from North America.
12GF Score
Get the complete analysis for AIFF
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AIFF has been successfully added to your 
